Boston Event 04/09 - Debt Financing for Early-Stage Biotech & Life Sciences Companies
March 27, 2024
by a lender from Audencia Business School in Boston, MA, USA
Is debt financing the right instrument to grow your Biotech or Life Sciences company?
Link to register here: https://www.faccne.org/events/events-calendar/e/event/debt-financing-for-early-stage-biotech-life-sciences-companies.html
At a time when raising capital may be challenging, Life Sciences and Biotech startups & early growth stage companies should evaluate debt financing, usually a form or capital that is more traditionally used by early-stage Tech companies or companies generating steady streams of cash flows.
• At what stage of a company’s life cycle is debt financing possible?
• What are the pros and cons of raising debt versus equity and what financing structures are available?
• Is it a tool you should consider for your own Biotech or Life sciences early growth stage company?
Find out key insights from some of the best experts in the field:
Fantastic relevant panel with collectively over 100 years of relevant experience.
• Marc de Garidel, CEO of Abivax, largest French biotech IPO on Nasdaq ever. Far-reaching biotech/pharma leadership with industry leaders, 12 years as CEO, experience both with debt financing (his current company secured $150 m in debt financing from two structured debt financing transactions in###-###-#### and equity financing (largest French biotech IPO ever on Nasdaq) .
• Janice Bourque, Managing Director, Life Sciences at Hercules Capital; Founder of MassBio (an organization dedicated to life sciences leadership), provides venture debt and equity to venture capital and private equity-backed life science companies at all stages of development.
• Seth Taylor, Co-founder, CBO, and CFO of SmartLabs, a series C company that makes capital investments in enterprise-grade R&D infrastructure and manufacturing and provides those as a service to biotech firms.Founder of one of Boston's most popular biotech networking venues: BiotechTuesday.
• Paul Enderle, Managing Director and Founder of BayCross Capital; At BayCross Capital, Paul helps address unmet capital needs for emerging companies in the venture, middle market, and small cap public markets.
• Nathan Meaux, Head of Northeast Life Sciences at Silicon Valley Bank; provides emerging companies with access to market insights, investors, and financial solutions on their path to growth. Expert in venture debt facilities underwriting, experience spanning over $1Bn in commitments in past ten years.
Link to register here: https://www.faccne.org/events/events-calendar/e/event/debt-financing-for-early-stage-biotech-life-sciences-companies.html
At a time when raising capital may be challenging, Life Sciences and Biotech startups & early growth stage companies should evaluate debt financing, usually a form or capital that is more traditionally used by early-stage Tech companies or companies generating steady streams of cash flows.
• At what stage of a company’s life cycle is debt financing possible?
• What are the pros and cons of raising debt versus equity and what financing structures are available?
• Is it a tool you should consider for your own Biotech or Life sciences early growth stage company?
Find out key insights from some of the best experts in the field:
Fantastic relevant panel with collectively over 100 years of relevant experience.
• Marc de Garidel, CEO of Abivax, largest French biotech IPO on Nasdaq ever. Far-reaching biotech/pharma leadership with industry leaders, 12 years as CEO, experience both with debt financing (his current company secured $150 m in debt financing from two structured debt financing transactions in###-###-#### and equity financing (largest French biotech IPO ever on Nasdaq) .
• Janice Bourque, Managing Director, Life Sciences at Hercules Capital; Founder of MassBio (an organization dedicated to life sciences leadership), provides venture debt and equity to venture capital and private equity-backed life science companies at all stages of development.
• Seth Taylor, Co-founder, CBO, and CFO of SmartLabs, a series C company that makes capital investments in enterprise-grade R&D infrastructure and manufacturing and provides those as a service to biotech firms.Founder of one of Boston's most popular biotech networking venues: BiotechTuesday.
• Paul Enderle, Managing Director and Founder of BayCross Capital; At BayCross Capital, Paul helps address unmet capital needs for emerging companies in the venture, middle market, and small cap public markets.
• Nathan Meaux, Head of Northeast Life Sciences at Silicon Valley Bank; provides emerging companies with access to market insights, investors, and financial solutions on their path to growth. Expert in venture debt facilities underwriting, experience spanning over $1Bn in commitments in past ten years.
from Audencia Business School in Boston, MA, USA